Drug Profile
UCB 35440
Alternative Names: UCB 35440-3Latest Information Update: 04 Feb 2017
Price :
$50
*
At a glance
- Originator UCB
- Class Antiallergics; Antiasthmatics; Piperazines
- Mechanism of Action 5-lipoxygenase inhibitors; Histamine H1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Allergic rhinitis; Asthma
Most Recent Events
- 03 Feb 2017 Discontinued - Phase-I for Allergic rhinitis (PO)
- 03 Feb 2017 Discontinued - Phase-II for Asthma (PO)
- 05 Aug 2004 Suspended - Phase-I for Allergic rhinitis (PO)